Analysis of number needed to treat for droxidopa in patients with symptomatic neurogenic orthostatic hypotension

Clément François, Gerald J Rowse, L Arthur Hewitt, Pamela Vo, Robert A Hauser, Clément François, Gerald J Rowse, L Arthur Hewitt, Pamela Vo, Robert A Hauser

Abstract

Background: Droxidopa is an orally active prodrug that significantly improved dizziness/lightheadedness measured using the Orthostatic Hypotension Symptom Assessment (OHSA) Item 1 in patients with neurogenic orthostatic hypotension (nOH) caused by primary autonomic failure (Parkinson disease, multiple system atrophy, and pure autonomic failure), dopamine β-hydroxylase deficiency, or nondiabetic autonomic neuropathy. The efficacy and safety of droxidopa were assessed by determining the number needed to treat (NNT) and the number needed to harm (NNH).

Methods: Data collected in randomized, placebo-controlled clinical studies in adults with a clinical diagnosis of symptomatic nOH were pooled for efficacy and safety analyses. NNT and NNH were calculated as reciprocals of the risk difference (difference in event rates) for droxidopa versus placebo.

Results: The NNT for droxidopa for improvement in OHSA Item 1 was <10. The NNH for adverse events (AEs) leading to discontinuation in the pooled studies was 81. The likelihood of being helped or harmed (LHH) calculated from pooled analysis of the NNT for ≥2 units of improvement in OHSA Item 1 score and the NNH for discontinuations due to AEs were 7.8, 8.8, 3.1, and 3.5 for weeks 1, 2, 4, and 8 after randomization, respectively.

Conclusions: Droxidopa is efficacious for treatment of nOH, with an NNT below 10 and an acceptable tolerability profile with NNH ranging from 23 to 302 in the pooled analysis of frequently occurring AEs. Based on the LHH for the pooled analysis at week 1, droxidopa is 7.8 times more likely than placebo to show a clinical benefit than result in discontinuation because of an AE.

Trial registrations: ClinicalTrials.gov identifiers: NCT00782340 , first received October 29, 2008; NCT00633880 , first received March 5, 2008; and NCT01176240 , first received July 30, 2010.

Keywords: Droxidopa; Neurogenic orthostatic hypotension; Number needed to harm; Number needed to treat; Risk reduction; nOH treatment benefit.

Figures

Fig. 1
Fig. 1
NNT for improvement of ≥2 units (a) and ≥50 % (b) in OHSA Item 1 (Dizziness/Lightheadedness) Score*. NNT = number needed to treat; OHSA = Orthostatic Hypotension Symptom Assessment; RD = risk difference (between event rates for droxidopa and placebo). *Error bars depicting the 95 % CIs are provided for statistically significant NNT values

References

    1. Freeman R, Wieling W, Axelrod FB, Benditt DG, Benarroch E, Biaggioni I, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res. 2011;21:69–72. doi: 10.1007/s10286-011-0119-5.
    1. Northera (droxidopa) Full Prescribing Information. Deerfield, IL: Lundbeck NA Ltd; 2014.
    1. Kaufmann H, Freeman R, Biaggioni I, Low P, Pedder S, Hewitt LA, et al. Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial. Neurology. 2014;83:328–335. doi: 10.1212/WNL.0000000000000615.
    1. Hauser RA, Hewitt LA, Isaacson S. Droxidopa in patients with neurogenic orthostatic hypotension associated with Parkinson’s disease (NOH306A) J Parkinsons Dis. 2014;4:57–65.
    1. Hauser RA, Isaacson S, Lisk JP, Hewitt LA, Rowse G. Droxidopa for the short-term treatment of symptomatic neurogenic orthostatic hypotension in Parkinson’s disease (NOH306B) Mov Disord. 2015;30:646–654. doi: 10.1002/mds.26086.
    1. Biaggioni I, Freeman R, Mathias CJ, Low P, Hewitt LA, Kaufmann H, et al. Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa. Hypertension. 2015;65:101–107. doi: 10.1161/HYPERTENSIONAHA.114.04035.
    1. Kaufmann H, Malamut R, Norcliffe-Kaufmann L, Rosa K, Freeman R. The orthostatic hypotension questionnaire (OHQ): validation of a novel symptom assessment scale. Clin Auton Res. 2012;22:79–90. doi: 10.1007/s10286-011-0146-2.
    1. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med. 1988;318:1728–1733. doi: 10.1056/NEJM198806303182605.
    1. Citrome L. Number needed to treat: what it is and what it isn’t, and why every clinician should know how to calculate it. J Clin Psychiatry. 2011;72:412–413. doi: 10.4088/JCP.11ac06874.
    1. Bender R. Calculating confidence intervals for the number needed to treat. Control Clin Trials. 2001;22:102–110. doi: 10.1016/S0197-2456(00)00134-3.
    1. Hufford MR, Shiffman S. Methodological issues affecting the value of patient-reported outcomes data. Expert Rev Pharmacoecon Outcomes Res. 2002;2:119–128. doi: 10.1586/14737167.2.2.119.
    1. Sharabi Y, Goldstein DS. Mechanisms of orthostatic hypotension and supine hypertension in Parkinson disease. J Neurol Sci. 2011;310:123–128. doi: 10.1016/j.jns.2011.06.047.
    1. Frith J, Newton JL. Validation of a questionnaire for orthostatic hypotension for routine clinical use. Geriatr Gerontol Int. 2016;16:785–90.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere